MacroGenics (MGNX) AI Stock Analysis

• Market Cap: $97.79M
• Dividend Yield: N/A
• Average Volume (3M): 1.41M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.08
• Revenue Growth: 255.31%
• EPS Growth: -141.39%
• Country: US
• Employees: 341
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.65
• Shares Outstanding: 63,090,324
• 10 Day Avg. Volume: 3,512,968
• 30 Day Avg. Volume: 1,405,887
• PEG Ratio: 0.09
• Price to Book (P/B): 2.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.55
• Enterprise Value/Market Cap: 4.37
• Enterprise Value/Revenue: 0.88
• Enterprise Value/Gross Profit: 3.12
• Enterprise Value/Ebitda: -1.33
• 1Y Price Target: $4.20
• Price Target Upside: 176.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 57 Neutral
• Price Target: $1.50 ▼(-1.32%Downside)

The overall score is driven by the financial performance challenges, particularly in cash flow and profitability. However, the recent corporate event provides a significant positive impact by enhancing the company's cash position, while technical analysis shows mixed signals. Valuation remains a concern with negative earnings, but the strategic agreement helps mitigate some financial risks.

Positive Factors

Financial Position

MGNX ended with $154.1M in cash and equivalents, providing an expected runway into the second half of 2026.

Pipeline Progress

MGNX's second B7-H3 ADC program, MGC026, has the potential to improve upon Vobra Duo and address a broad range of B7-H3-expressing tumors.

Program Development

The decision to discontinue vobra duo is seen as positive for the company as it allows MGNX to reallocate resources to programs with a higher probability of success.

Negative Factors

Clinical Risks

Risks include clinical setbacks with MGC026, lorigerlimab, MGC028, and MGC030, competitive landscape risks, partnership risks, and possible long-term dilution risk.

Financial Performance

MacroGenics reported a full-year 2024 net loss of $1.07 per share, slightly wider than the previous forecast of a net loss of $0.95 per share.

Stock Valuation

The 12-month price target has been lowered to $2 per share from the prior $4 per share.

MacroGenics Business Overview & Revenue Model

Company Description

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

How the Company Makes Money

MacroGenics makes money primarily through the development and commercialization of its proprietary monoclonal antibody-based therapies. The company generates revenue through strategic collaborations and licensing agreements with major pharmaceutical companies, which provide upfront payments, milestone payments, and royalties on product sales. These partnerships are integral to its revenue model as they provide funding and resources necessary for the advancement of its clinical pipeline. Additionally, MacroGenics may secure government grants or funding to support specific research initiatives, contributing to its financial resources. The company's revenue streams are heavily dependent on the success of its clinical trials and the eventual approval and commercialization of its therapies.

MacroGenics Financial Statement Overview

Summary

MacroGenics exhibits revenue growth but faces ongoing profitability challenges, with negative EBIT and net income. The balance sheet is stable with manageable debt, yet cash flow remains a concern due to negative free cash flow.

Income Statement

MacroGenics shows a mixed performance in terms of revenue and profitability. The TTM (Trailing-Twelve-Months) revenue is up from the previous year, indicating growth, but the company continues to report negative EBIT and net income, signaling ongoing operational challenges. Gross profit margins are strong, but net profit margins remain negative, reflecting the high costs affecting overall profitability.

Balance Sheet

The balance sheet of MacroGenics highlights a moderate financial position. The debt-to-equity ratio is relatively low, suggesting manageable leverage levels. However, the company's return on equity is negative due to consecutive net losses. The equity ratio indicates a fair portion of the assets are financed by equity, providing some stability.

Cash Flow

Cash flow analysis reveals challenges in generating positive cash flows. The company reports negative free cash flow in the TTM, although there is a slight improvement in operating cash flow. The free cash flow to net income ratio remains negative, indicating difficulties in turning net losses into cash.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
152.43M	148.34M	57.19M	151.94M	75.64M	97.76M
	Gross Profit
136.84M	136.04M	48.97M	144.56M	72.99M	-95.44M
	EBIT
-99.45M	-110.58M	-168.24M	-121.42M	-202.79M	-131.06M
	EBITDA
-47.33M	-57.37M	2.02M	-107.89M	-190.86M	-117.78M
	Net Income Common Stockholders
-55.81M	-66.97M	-9.06M	-120.02M	-190.86M	-117.78M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
154.14M	201.67M	229.81M	154.35M	243.62M	272.53M
	Total Assets
224.56M	261.65M	298.42M	280.47M	335.25M	378.74M
	Total Debt
37.47M	37.46M	33.97M	34.83M	25.47M	29.25M
	Net Debt
-108.10M	-145.38M	-66.98M	-74.05M	-98.00M	-151.88M
	Total Liabilities
145.45M	145.60M	145.81M	138.46M	95.63M	82.86M
	Stockholders Equity
79.12M	116.06M	152.61M	142.01M	239.62M	295.88M
Cash Flow		Free Cash Flow
-72.40M	-72.08M	-79.97M	-90.58M	-150.03M	-117.80M
	Operating Cash Flow
-69.62M	-68.37M	-78.20M	-86.96M	-143.83M	-111.90M
	Investing Cash Flow
134.41M	149.30M	-80.08M	70.72M	-36.61M	-7.79M
	Financing Cash Flow
430.00K	960.00K	150.36M	1.66M	122.78M	174.34M

MacroGenics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.52
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGNX, the sentiment is Negative. The current price of 1.52 is below the 20-day moving average (MA) of 1.54, above the 50-day MA of 1.49, and below the 200-day MA of 2.72, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 48.24 is Neutral, neither overbought nor oversold. The STOCH value of 31.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGNX.

MacroGenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MGNX	57 Neutral	$97.79M	―	-60.25%	―	255.31%	-141.39%
VXRT	54 Neutral	$122.60M	―	-114.74%	―	433.43%	49.04%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
CRBU	46 Neutral	$107.89M	―	-52.76%	―	-70.31%	-11.68%
PLRX	37 Underperform	$90.24M	―	-63.22%	―	-100.00%	-26.44%
TNYA	36 Underperform	$97.73M	―	-76.21%	―	―	23.55%
ELTX	30 Underperform	$126.94M	―	-744.59%	―	―	27.65%

MacroGenics Corporate Events

MacroGenics Enters Royalty Purchase Agreement with Sagard

On June 9, 2025, MacroGenics, Inc. entered into a Royalty Purchase Agreement with Sagard Healthcare Partners, selling its rights to receive royalties on global net sales of ZYNYZ (retifanlimab-dlwr) starting July 1, 2025. MacroGenics received a $70 million upfront payment, which extends its cash runway through the first half of 2027. Sagard will collect royalties until they reach $140 million, after which MacroGenics will resume collecting royalties. This agreement allows MacroGenics to retain other economic interests in ZYNYZ, including potential development and commercial milestones, while continuing to support global manufacturing needs.

The most recent analyst rating on (MGNX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.

MacroGenics Holds Annual Stockholders Meeting on May 21

On May 21, 2025, MacroGenics, Inc. held its Annual Meeting of Stockholders, where approximately 82% of the company’s common stock was represented. During the meeting, stockholders elected four Class III directors for a three-year term, ratified the appointment of Ernst & Young LLP as the independent auditor for 2025, approved executive compensation, and amended the 2023 Equity Incentive Plan to increase available shares by 1,250,000. These decisions reflect the company’s ongoing governance and strategic planning efforts, potentially impacting its operational focus and shareholder value.

The most recent analyst rating on (MGNX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.